SHIONOGI INC

Shionogi Inc. specializes in the manufacturing of pharmaceutical preparations, with demonstrated expertise in the production and supply of clinical-grade drugs, hematology-related therapeutics, and specialty pharmaceuticals for federal healthcare systems. The company’s technical capabilities center on GMP-compliant manufacturing processes, sterile product formulation, and quality assurance systems aligned with FDA and VA procurement standards. Their focus on hematology and drug delivery platforms suggests deep proficiency in complex dosage forms and controlled-release technologies, positioning them as a reliable source for mission-critical medications used in veteran care settings. Shionogi Inc. maintains a direct and focused relationship with the Department of Veterans Affairs, supplying pharmaceutical products under the Federal Supply Schedule for use in VA medical facilities. This engagement reflects a proven ability to meet the stringent regulatory, logistical, and dosing requirements of large-scale federal healthcare distribution networks, particularly for specialized therapeutics requiring consistent batch integrity and traceability. The contractor’s primary industry focus is NAICS 325412—Pharmaceutical Preparation Manufacturing—which encompasses the formulation, blending, packaging, and quality control of finished drug products intended for human use. Their market positioning is narrow but highly specialized, serving the niche segment of government-contracted pharmaceuticals where regulatory compliance, supply chain reliability, and therapeutic specificity are paramount. As a 2L entity headquartered in Florham Park, New Jersey, Shionogi Inc. operates as a corporate manufacturer with no active government certifications on record. Their geographic footprint is centered in the Northeast, with a federal market strategy anchored in direct supply to VA medical centers through established procurement channels. The company’s presence is defined by precision manufacturing and regulatory adherence rather than broad diversification across federal agencies.